microRNA ‑572 functions as an oncogene and a potential biomarker for renal cell carcinoma prognosis.

microRNA‑572 functions as an oncogene and a potential biomarker for renal cell carcinoma prognosis. Oncol Rep. 2018 Aug 17;: Authors: Pan X, Li Z, Zhao L, Quan J, Zhou L, Xu J, Xu W, Guan X, Li H, Yang S, Gui Y, Lai Y Abstract Renal cell carcinoma (RCC) is the third most common urological malignancy in the USA and represents 2‑3% of all adult malignancies. Furthermore, the incidence of RCC has been progressively increasing over recent years. Although the morbidity of treatment has decreased with the use of multidisciplinary synthetic therapy, the prognosis of terminal cancer remains poor, with a 5‑year survival rate of 5‑10%. MicroRNAs (miRs) have been correlated with the regulation of 30‑60% of the protein-coding genes and act as oncogenes or anti‑oncogenes in RCC. Considering this research, miRNAs are likely to be the biomarkers for tumor diagnosis, prognosis and the targets for RCC management. In the present study, 42 formalin‑fixed paraffin‑embedded RCC samples were used. The expression of miR‑572 and the role of miR‑572 in RCC cell proliferation, migration and apoptosis was determined by performing reverse transcription‑quantitative polymerase chain reaction analysis, wound scratch assays, cell proliferation assays, Transwell assays and flow cytometry assays, respectively. Further experiments were conducted to clarify the correlation between miR‑572 expression and clinicopathological variables or overall ...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research